Global Herpes Labialis (Oral Herpes) Market Size By Product (Acyclovir, Valacyclovir, Famciclovir, Docosanol, Penciclovir), By Routes Of Administration (Topical, Oral, Parenteral), By Geographic Scope And Forecast

Herpes Labialis (Oral Herpes) Market Size And Forecast

Herpes Labialis (Oral Herpes) Market size was valued at USD 2.24 Billion in 2021 and is projected to reach USD 3.41 Billion by 2030, growing at a CAGR of 4.78% from 2022 to 2030.

Factors driving the market include the rising prevalence of herpes labialis in children and adults around the world, new drug types, and modes of action, rising generic penetration, frequent changes in disease therapy, and rising consumer awareness. However, the market is constrained by government restrictions governing drug approvals and a lack of awareness and information about herpes labialis. The Global Herpes Labialis (Oral Herpes) Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.

Global Herpes Labialis (Oral Herpes) Market Definition

HSV is a contagious infection that spreads by saliva, sperm, and vaginal fluids and causes painful blisters or ulcers. Physical examinations, fluid collection, and blood testing are commonly used to diagnose it. Antiviral drugs including acyclovir, famciclovir, and valacyclovir are now the most effective therapy options for patients. To assist ease symptoms, reduce the intensity and frequency of outbreaks, and limit virus transmission, these drugs can be given orally or intravenously (IV).

Herpes labialis is most commonly contracted in childhood and remains dormant in the nervous system to some extent. Newborn babies and people who are immunosuppressed, on the other hand, suffer major health repercussions. Herpes labialis is most commonly contracted in childhood and remains dormant in the nervous system to some extent. Newborn babies and people who are immunosuppressed, on the other hand, suffer major health repercussions.

Many infected people live as a carrier without any symptoms and pass on the virus to other healthy people who might develop the symptoms when affected by the virus. HSV type 1 is the cause of the majority of oral herpes, and HSV type 2 is responsible for the rest cases. Oral herpes makes it difficult for the infected person to eat, drink, and talk as it causes severe pain in the affected areas. There are no proven medications for a proper cure of the disease but certain drugs can reduce the symptoms caused by the disease.

Global Herpes Labialis (Oral Herpes) Market Overview

Herpes infection was first contracted through non-sexual contact throughout childhood or adolescence. However, epidemiology has shifted in a negative direction recently. The HSV-1 virus is currently attacking the genitals at an unpredictable rate, affecting the majority of the population. Women are the most afflicted by the illness. The virus causes cold sores around women’s genitals, which cause itching and rashes, making them uncomfortable. Businesses have noticed an increase in demand for novel pharmaceuticals and treatments for herpes labialis due to the increasing incidence of the HSV-1 virus in countries such as Bulgaria, the Netherlands, Germany, and some nations in North America. As a result, the worldwide Herpes Labialis (Oral Herpes) Market is now experiencing strong expansion.

With the rising prevalence of herpes simplex virus (HSV) infections such as genital herpes, Herpes Simplex Virus type 1 (HSV1), and Herpes Simplex Virus type 2 (HSV2) around the world, demand for HSV drugs and therapeutics is rapidly rising, which is expected to drive the global Herpes Labialis (Oral Herpes) Market during the forecast period. Herpes Simplex Virus -1 and Herpes Simplex Virus -2 are the two kinds of Herpes Simplex Virus. About one in every ten people is infected with Herpes Simplex Virus type-2, which accounts for about half of genital ulcer disease cases and three-quarters of herpes simplex cases. As a result, there is an increasing need for a Herpes Simplex Virus -2 vaccine as well as universal access to sexual & reproductive health services, which is projected to drive the Herpes Labialis (Oral Herpes) Market over the forecast period. As a result, increased herpes simplex virus prevalence is predicted to promote market growth.

There is no prophylactic or therapeutic vaccine available on the market for Herpes Labialis. In clinical trials, however, only a few trials have demonstrated encouraging results for the prevention and treatment of HSV. Although animal studies have shown promise in clinical trials, the pathophysiology of the disease differs between animals and people, making it difficult to replicate the results in human trials. Clinical trials in mice and guinea pigs, for example, have yielded more good outcomes than human trials, since human HSV infection differs from animal HSV infection. These reasons have hampered the global market for herpes simplex virus (HSV) vaccinations. Over the projection period, rising government spending on the pharmaceutical sector, and the availability of cost-effective treatments, are projected to offer new revenue opportunities for firms operating in the target market.

Furthermore, increasing public-private partnerships in R&D activities is projected to help the global market growth to some level. Soon, increased R&D is expected to provide lucrative prospects. The introduction of new medicines is supporting the market’s growth. Collaborations between market participants and colleges, as well as mergers and acquisitions among the biggest corporations, have been recent market trends. The pandemic of COVID-19 has had a substantial impact on market growth. The researcher established the link between the herpes simplex virus and the SARS-CoV-2 virus in many studies, which impacted the market positively due to the increased demand for antiviral drugs for treatment. COVID-19 and its impact on people with Herpes Simplex Virus are also expected to drive growth in the studied market (HSV).

Global Herpes Labialis (Oral Herpes) MarketSegmentation Analysis

The Global Herpes Labialis (Oral Herpes) Market is Segmented on the basis of Product, Routes Of Administration, and Geography.

Herpes Labialis (oral Herpes) Market, By Product

• Acyclovir
• Valacyclovir
• Famciclovir
• Docosanol
• Penciclovir

Based on Product, the market is segmented into Acyclovir, Valacyclovir, Famciclovir, Docosanol, and Penciclovir. During the projection period, the Acyclovir segment is expected to hold a big part of the market, since these drugs are frequently utilized and trusted due to their extremely successful outcomes. Additionally, continuous research and development in the field, as well as market leaders’ launches of new medications in the segment, would boost the acyclovir segment’s growth in the Herpes Labialis (Oral Herpes) Market during the projection period. Valacyclovir is thought to be more effective than previously used drugs like Acyclovir because it only requires a small number of doses, has a long-term effect on infection, and has an immediate effect on virus infection; as a result, the segment is expected to grow rapidly during the forecast period.

Herpes Labialis (oral Herpes) Market, By Routes of Administration

• Topical
• Oral
• Parenteral

Based on Routes Of Administration, the market is segmented into Topical, Oral, and Parenteral. Because it is a highly preferred method of eating drugs and is simple to consume, the oral segment represents a significant share of the market and is expected to grow at a significant rate over the forecast period. Oral pharmaceuticals are frequently recommended in conjunction with topically delivered drugs, which is projected to boost demand for both oral and topical medications.

Herpes Labialis (Oral Herpes) Market, By Geography

• North America
• Europe
• Asia Pacific
• Rest of the World

Based on Geography, the Global Herpes Labialis (Oral Herpes) Market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. North America is predicted to lead the global market for herpes labialis medications, and this dominance is expected to continue over the forecast period. This is due to the presence of large firms operating in the region, as well as a well-developed pharmaceutical infrastructure for R&D operations. Other factors predicted to promote the target market’s growth in this region include increased merger and acquisition activity between regional and multinational competitors.

Key Players

The “Global Herpes Labialis (Oral Herpes) Market” study report will provide valuable insight with an emphasis on the global market. The major players in the market are GlaxoSmithKline LLC, Emcure Pharmaceuticals Ltd, Fresenius Kabi, Carlsbad Tech, Teva Pharmaceutical Industries, Zydus Cadila, Livzon, Hikma Pharmaceuticals, Apotex Inc, and Torrent Pharmaceutical Ltd. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Key Developments

• In October 2021, the efficacy of UB-621, a best-in-class long-acting treatment for genital herpes caused by herpes simplex viruses 1 and 2, was investigated in collaboration with Cheng Kung University’s Department of Microbiology and Immunology (HSV 1 and HSV2) and Shanghai Public Health Clinical Centre.
• In March 2021, GlaxoSmithKline (GSK) and Precision Vaccinations started a small Phase 1 clinical study for the HSV vaccine, a herpes simplex type 2 (HSV-2) candidate (GSK4108771A). As a result, such innovations help the region’s studied market flourish.

Report Scope

Top Trending Reports